// App-Quantinova.ai

P312 : Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI

Researchers

Presenter

  • B E Sands

Principal Investigators

  • L Peyrin-Biroulet

  • C Marano

  • C D O'Brien

  • H Zhang

  • J Johanns

  • P Szapary

  • D Rowbotham

  • R W Leong

  • R P Arasaradnam

  • S Danese

  • G Van Assche

  • S Targan

  • W J Sandborn

Medical Centers

  • Icahn School of Medicine at Mount Sinai, New York, NY

  • Nancy University Hospital, Université de Lorraine, Nancy, France

  • Janssen Research and Development, LLC, Spring House, PA

  • Janssen Research and Development, LLC, Spring House, PA

  • Auckland City Hospital, Auckland, New Zealand

  • University of Auckland, Auckland, New Zealand

  • Concord Hospital, Sydney NSW, Australia

  • Macquarie University Hospital, Sydney, Australia

  • Warwick Medical School, University Hospital Coventry, Warwickshire, UK

  • Humanitas Research Hospital, Rozzano, Italy

  • University of Leuven, KUL, Leuven, Belgium

  • Cedars-Sinai Medical Center, Los Angeles, CA

  • University of California, San Diego, La Jolla, CA

Locations

  • United States

  • France

  • New Zealand

  • Australia

  • United Kingdom

  • Italy

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

Biomarkers

  • N/A

Drug/Treatment

  • Ustekinumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved